

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

IMMUNOMEDICS INC
Form 8-K
September 06, 2005

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 2, 2005

Immunomedics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	000-12104	61-1009366
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

300 American Road, Morris Plains, New Jersey	07950
-----	-----
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (973) 605-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

ITEM 8.01. OTHER EVENT

On September 2, 2005, Immunomedics, Inc., a Delaware corporation (the

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

"Company"), received notification from The Nasdaq Stock Market ("Nasdaq") informing the Company that the Nasdaq Listing and Qualification Panel has determined that the Company will continue to be listed on The NASDAQ Stock Market. On September 6, 2005, the Company issued a press release to announce its receipt of this notification from the NASDAQ. A copy of the press release is attached hereto as Exhibit 99.1.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits:

99.1 Press release dated September 6, 2005, titled
"Immunomedics Announces Positive Ruling from Nasdaq
Appeal Panel."

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 6, 2005

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan

Cynthia L. Sullivan
President and Chief Executive Officer

-3-